155 related articles for article (PubMed ID: 11821463)
1. Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306.
Sekine I; Nishiwaki Y; Ogino T; Yokoyama A; Saito M; Mori K; Tsukiyama I; Tsuchiya S; Hayakawa K; Yoshimura K; Ishizuka N; Saijo N
J Clin Oncol; 2002 Feb; 20(3):797-803. PubMed ID: 11821463
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer.
Atagi S; Kawahara M; Hosoe S; Ogawara M; Kawaguchi T; Okishio K; Naka N; Sunami T; Mitsuoka S; Akira M
Lung Cancer; 2002 Apr; 36(1):105-11. PubMed ID: 11891041
[TBL] [Abstract][Full Text] [Related]
3. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Yamamoto N; Nakagawa K; Nishimura Y; Tsujino K; Satouchi M; Kudo S; Hida T; Kawahara M; Takeda K; Katakami N; Sawa T; Yokota S; Seto T; Imamura F; Saka H; Iwamoto Y; Semba H; Chiba Y; Uejima H; Fukuoka M
J Clin Oncol; 2010 Aug; 28(23):3739-45. PubMed ID: 20625120
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
6. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
[TBL] [Abstract][Full Text] [Related]
8. [Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer].
Nakano K; Kumagai K; Ishida H; Kohjima N; Hiramoto T; Hada Y
Gan To Kagaku Ryoho; 1996 Jan; 23(1):57-61. PubMed ID: 8546470
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M
Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
[TBL] [Abstract][Full Text] [Related]
11. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Furuse K; Fukuoka M; Kawahara M; Nishikawa H; Takada Y; Kudoh S; Katagami N; Ariyoshi Y
J Clin Oncol; 1999 Sep; 17(9):2692-9. PubMed ID: 10561343
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
[TBL] [Abstract][Full Text] [Related]
15. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
18. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
